AbbVie agreed to acquire Apogee Therapeutics for a total equity valuation of approximately $10.9 billion. Under the financial terms of the definitive merger agreement, AbbVie offered $135.11 per share in cash for all outstanding shares of Apogee, representing a substantial premium over the biotechnology company's prior market trading levels to secure its promising immunology pipeline.